Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 19;22(1):116.
doi: 10.1186/s12872-022-02548-2.

Does Losartan reduce the severity of COVID-19 in hypertensive patients?

Mohammadreza Mirjalili  1 , Moslem Taheri Soodejani  2 , Mehdi Raadabadi  3 , Ali Dehghani  4 , Fateme Salemi  5
Affiliations

Does Losartan reduce the severity of COVID-19 in hypertensive patients?

Mohammadreza Mirjalili et al. BMC Cardiovasc Disord. .

Abstract

Background: One of the global problems is to control the coronavirus epidemic, and the role of different medicines is still unknown to policymakers. This study was conducted to evaluate the effects of losartan on the mortality rate of COVID-19 in hypertensive patients.

Methods: The research sample of analytical study included 1458 patients presenting to COVID-19 diagnostic centers in Yazd that were examined in the first six months of 2020. Data were analyzed using descriptive statistics as well as chi-square, Fisher's exact test, t test, and logistic regression.

Results: Of 1458 subjects that were studied, 280 were hypertensive of whom 179 tested positive for SARS-CoV-2 PCR. The results showed a lower chance of death by more than 5 times in hypertensive patients who used losartan (P = 0.003). Moreover, regarding the effect of losartan on the prevention of COVID-19 in hypertensive patients, it was found that this medicine played a protective role although this relationship was not statistically significant (P = 0.86).

Conclusions: The results showed that losartan reduced the chance of mortality in hypertensive patients. It is recommended that the effect of losartan and other blood pressure medicines on COVID-19 patients be investigated in larger studies as well as laboratory investigations.

Keywords: Blood pressure/hypertension; Losartan; Mortality; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

All authors declare that they have no conflict of interest regarding this study.

Figures

Fig. 1
Fig. 1
Sample flow diagram detailing included subjects and exclusion criteria
See this image and copyright information in PMC

References

    1. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020;12(2):135. doi: 10.3390/v12020135. - DOI - PMC - PubMed
    1. Alshahrani MS, Sindi A, Alshamsi F, Al-Omari A, El Tahan M, Alahmadi B, et al. Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus. Ann Intensive Care. 2018;8(1):1–10. doi: 10.12659/msm.925364. - DOI - PMC - PubMed
    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. doi: 10.1016/S0140-6736(20)30566-3. - DOI - PMC - PubMed
    1. Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, et al. Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study. Diabetes care. 2020;43(7):1382–91. doi: 10.2337/dc20-0598. - DOI - PubMed
    1. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infection. 2020;80(6):e14-e8. doi: 10.1016/j.jinf.2020.03.005. - DOI - PMC - PubMed

Publication types